Literature DB >> 2400226

Chronic respiratory morbidity after prolonged and premature rupture of the membranes.

P J Thompson1, A Greenough, K Nicolaides.   

Abstract

Twenty one surviving infants of pregnancies complicated by rupture of the membranes during the second trimester that lasted at least one week have been followed up for a median of 15 months. Five infants (24%) had recurrent respiratory problems (episodes of wheezing and coughing occurring at least once a week) which related significantly to the use of neonatal ventilation and to very preterm delivery. Five of the 18 infants who were born preterm and with birth weights of less than 2500 g had recurrent respiratory symptoms (28%). This compares favourably with an incidence of symptoms of 67% among surviving low birthweight infants born at this hospital after pregnancies not complicated by premature rupture of the membranes. Neither recurrent respiratory symptoms nor admission to hospital for chest related disorders were associated with the timing of onset or duration of rupture of the membranes. We conclude that, among survivors of premature rupture of the membranes, chronic respiratory morbidity would best be prevented by avoiding very preterm delivery, regardless of the duration of the rupture.

Entities:  

Mesh:

Year:  1990        PMID: 2400226      PMCID: PMC1792476          DOI: 10.1136/adc.65.8.878

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  19 in total

1.  Treatments of preterm premature rupture of the membranes: a meta-analysis.

Authors:  A Ohlsson
Journal:  Am J Obstet Gynecol       Date:  1989-04       Impact factor: 8.661

2.  Randomized trial of artificial surfactant (ALEC) given at birth to babies from 23 to 34 weeks gestation.

Authors:  C J Morley; A Greenough; N G Miller; A D Bangham; J Pool; S Wood; M South; J A Davis; H Vyas
Journal:  Early Hum Dev       Date:  1988-05       Impact factor: 2.079

3.  Neonatal pulmonary hypoplasia after prolonged leakage of amniotic fluid.

Authors:  M Perlman; J Williams; M Hirsch
Journal:  Arch Dis Child       Date:  1976-05       Impact factor: 3.791

4.  Premature rupture of the membranes before 28 weeks: conservative management.

Authors:  S N Beydoun; S Y Yasin
Journal:  Am J Obstet Gynecol       Date:  1986-09       Impact factor: 8.661

5.  Oligohydramnios, cause of the nonrenal features of Potter's syndrome, including pulmonary hypoplasia.

Authors:  I T Thomas; D W Smith
Journal:  J Pediatr       Date:  1974-06       Impact factor: 4.406

6.  Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan; D Y Porter
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

7.  Neonatal outcome after prolonged rupture of the membranes starting in the second trimester.

Authors:  M Blott; A Greenough
Journal:  Arch Dis Child       Date:  1988-10       Impact factor: 3.791

8.  Pregnancy outcome after premature rupture of the membranes at or before 26 weeks' gestation.

Authors:  J M Bengtson; L J VanMarter; V A Barss; M F Greene; R E Tuomala; M F Epstein
Journal:  Obstet Gynecol       Date:  1989-06       Impact factor: 7.661

9.  Maternal and perinatal outcome of expectant management of premature rupture of membranes in the midtrimester.

Authors:  M Moretti; B M Sibai
Journal:  Am J Obstet Gynecol       Date:  1988-08       Impact factor: 8.661

10.  Continuing morbidity in extremely low birthweight infants.

Authors:  E Bowman; V Y Yu
Journal:  Early Hum Dev       Date:  1988-12       Impact factor: 2.079

View more
  2 in total

1.  Pulmonary hypoplasia presenting as persistent tachypnoea in the first few months of life.

Authors:  N R Aiton; G F Fox; S Hannam; C M Stern; A D Milner
Journal:  BMJ       Date:  1996-05-04

2.  Longitudinal assessment of infant lung function following pregnancies complicated by prolonged and preterm rupture of the membranes.

Authors:  P Thompson; A Greenough; K H Nicolaides
Journal:  Eur J Pediatr       Date:  1992-06       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.